Why XENE fell 20.7% on Sep 17 2026: clinical safety pause
XENE-20.7%on Thu Sep 17 2026
Xenon Pharmaceuticals Inc was down 20.7% on the day at $45.00, ranked #1 on 61.2× its usual five-minute volume, when TapeRank recorded this drop at 16:11 ET during after hours. TapeRank recorded 2 events for XENE that day, between 16:02 and 16:11 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 16:02 ETUNEXPLAINED MOVE · AFTER-HOURS
$46.05 · ▼ 18.9% ON THE DAY · 1.0× 5M RVOL · RANK #17
UNEXPLAINEDNO FILINGS · RULEXENE is down 18.9% on the day on 1.0x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 16:02 ET · <1 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 16:02 ET
LAST46.05DAY▼ 18.9%5 MIN▼ 19.75%5M RVOL1.0×5M $VOL$2.0MFLOAT*96.7MRANK#17SESSIONAFTER-HOURSVWAP57.57HOD58.15LOD46.05OR HIGH—OR LOW—PREV CLOSE56.76PM HIGH—PM LOW—GAP▲ 1.48%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 16:11 ETMOVER · AFTER-HOURS
$45.00 · ▼ 20.7% ON THE DAY · 61.2× 5M RVOL · RANK #1
JUSTIFIEDCONFIDENCE5/5XENE fell 8.6% after voluntarily pausing enrollment of new patients in ongoing depression studies because of neuropsychiatric adverse events. The FDA filing and completed enrollment are positive, but the unexpected safety-related pause is the more immediate market-moving development and reasonably explains the decline.
WHYAn 8.6% drop is proportionate to a precautionary clinical-study enrollment pause involving adverse events, despite the simultaneous NDA submission and progress updates.ANALYZED 16:07 ET · 3 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 16:11 ET
LAST45.00DAY▼ 20.7%5 MIN▼ 7.94%5M RVOL61.2×5M $VOL$2.0MFLOAT*96.7MRANK#1SESSIONAFTER-HOURSVWAP57.01HOD58.15LOD45.12OR HIGH—OR LOW—PREV CLOSE56.76PM HIGH—PM LOW—GAP▲ 1.48%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $57.60, +1.5% on the previous close of $56.76
- 09:50 ETRegular-session high, $58.15
- 13:34 ETRegular-session low, $56.87
- 15:59 ETLast trade of the regular session, $57.36, +1.1% on the previous close of $56.76
- Volume: 697K shares in regular hours
XENE opened at $57.60 and reached $58.15 early before sliding to $56.87, then finished the regular session at $57.36, still above the previous close. After the session, TapeRank tied the sharper move to the company’s voluntary pause of new enrollment in ongoing depression studies following neuropsychiatric adverse events, despite its FDA filing for azetukalner and progress toward enrollment in another study. TapeRank later recorded the stock at $46.05 and then $45.00, its largest move at -20.7%; it also recorded an unexplained move, with no filings or headlines within 24 hours under its rule.
WRITTEN THU OCT 15 2026 17:51 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 16:05 ETXenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain ActiveBenzinga
- 16:05 ETXenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027Benzinga
- 16:02 ETXenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDABenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list